Opyl Limited announced changes to its senior leadership with Dr Hugo Stephenson joining to lead Opin, Michelle Gallaher moving to General Manager of TrialKey and Mark Ziirsen stepping in as the Executive Chairman. These changes follow the Board-led strategic review focused on identifying pathways for accelerating the growth of Opin and developing pathways to commercialise TrialKey. To better support and drive its strategic priorities, the Board announced a realignment of internal resources.

As a result, Michelle Gallaher has permanently stepped down as CEO of Opyl Limited, with immediate effect, and will transition to the role of GM TrialKey for a specified period. In her new role, Michelle will work alongside Executive Director and CTO, Damon Rasheed, on further development of the TrialKey platform. The Board is delighted to announce that following his recent appointment as Strategic Advisor to the Board, Dr Hugo Stephenson has agreed to join the company to lead Opin, the company's clinical trial recruitment business.

In this role, Dr Stephenson will specifically focus on: Accelerating recruitment for ANZ-based clinical trials and health programs; Streamlining Opin's business model to align with ANZ client needs; Unlocking new business opportunities in patient community growth and management; Broadening Asia Pacific partnerships with research sites, healthcare institutions and advocacy groups; Pursuing M&A opportunities in the Asia Pacific region; and Cultivating global growth opportunities. For the near term, Mr. Mark Ziirsen, Executive Chair will assume expanded executive duties, spending more time in the Melbourne head office, to provide support for these management changes.